Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Had been taking a sulfonylurea for at least 4 weeks prior to the initiation of the observation period (Week -12).~2. Had been taking glimepiride at a stable dose regimen (1, 2, 3 or 4 mg/day, once or twice daily in the morning or in the morning and evening, before or after meal) for at least 12 weeks prior to the initiation of the treatment period (Week 0).~3. Had glycosylated hemoglobin (HbA1c) of 7.0% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).~4. Had an HbA1c difference between 4 weeks after the initiation of the observation period (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being within 10.0%\* of the value at 4 weeks after the initiation of the observation period (Week -8) (\*rounded off to the first decimal place).~5. Was receiving specific diet and exercise (if any) therapies during the observation period.~Exclusion Criteria:~1. Had taken other diabetic medications than glimepiride within 12 weeks before the initiation of the treatment period (Week 0).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Alogliptin 12.5 mg QD and Glimepiride QD or BID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 25 mg QD and Glimepiride QD or BID (Type: ACTIVE_COMPARATOR): None
- Glimepiride 1, 2, 3 or 4 mg QD or BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).